ABSTRACT
The World Federation of Haemophilia (WFH) estimates that worldwide, approximately 70% of patients with hemophilia are underdiagnosed and untreated. Most live in developing countries. Although in developed countries the life expectancy of hemophiliacs is close to that of healthy persons, this is not the case in developing countries. Great disparity also exists in the treatment of hemophiliacs, especially when this relates to available factor concentrates. There are many reasons for the inadequate care of hemophilic patients: the perception of rarity of the disease; lack of laboratory facilities to diagnose the disorder; lack of understanding of the disorder by patients, their relatives, and even healthcare providers; poorly developed blood bank facilities; and lack of adequate factor supply are just some examples. The WFH attempts to address many of these issues by establishing hemophilia care programs and by educating and training healthcare practitioners so that a healthcare team can be organized that attempts to ameliorate these problems and provides treatment options. In the last few years, a considerable number of developing countries have been organized to deliver at least a minimum of care, and attempts have been made to obtain support from appropriate governmental sources.
KEYWORDS
Hemophilia - World Federation of Haemophilia - educational programs - treatment centers - outreach programs
REFERENCES
-
1 O'Mahony B. Global haemophilia care: challenges and opportunities. Lecture presented at: XXV International Congress of the WFH May 20, 2002 Seville, Spain;
-
2 Anonymous .WFH Global Survey Data 2002. Montreal; WFH 2002
-
3
Evatt B.
Observations from Global Survey 2001: an emerging database for progress.
Haemophilia.
2002;
8
153-156
-
4
Srivastava A, Chuansumrit A, Chandy M, Duraisamy G, Karabus C.
Management of haemophilia in the developing world.
Haemophilia.
1998;
4
474-480
-
5
Globe D, Cunningham W, Andersen R et al..
The Haemophilia Utilization Group Study: Cost of out-patient, in-patient and pharmaceutical care.
Int J Ped Oncol Hematol.
2001;
7
87-100
-
6 Anonymous .Guidelines for the Development of a National Programme for Haemophilia, 1996. Geneva, Switzerland; WFH/WHO 1996
-
7
Evatt B L, Robillard L.
Establishing haemophilia care in developing countries: using data to overcome the barrier of pessimism.
Haemophilia.
2000;
6
131-134
-
8
Rickard K.
The International Hemophilia Training Centres of the World Federation of Hemophilia: a 30-year review.
Haemophilia.
2000;
6
471-473
-
9 Anonymous .Improving Care Beyond Our Borders: A Twinning Guide for Hemophilia Treatment Centres. Montreal; WFH 2002
-
10 Anonymous .Haemophilia in Pictures. Montreal; WFH 1996
-
11 Anonymous .Diagnosis of Haemophilia and Other Bleeding Disorders: A Laboratory Manual. Montreal; WFH 2000
-
12 Anonymous .Key Issues in Haemophilia Treatment. Part 1: Products. Part 2: Organizing a National Programme for Comprehensive Haemophilia Care. Monograph: Facts and Figures 1. Montreal; WFH 1998
-
13 Lloyd S. The Preparation of Single Donor Cryoprecipitate. Monograph: Facts and Figures 2. Montreal; WFH 1997
-
14 Petersen I P, Bird A R. Small Pool Heat Treated Intermediate Purity Factor VII Concentrate. Monograph: Facts and Figures 3. Montreal; WFH 1997
-
15 Teitel J. Viral Safety of Coagulation Factor Concentrates. Monograph: Facts and Figures 4. Montreal; WFH 1997
-
16 Contract Fractionation .Monograph: Facts and Figures 5. Montreal; WFH 1998
-
17 Kasper C K, Costa e Silva M. Registry of Clotting Factor Concentrates. Monograph: Facts and Figures 6. Montreal; WFH 2000
-
18 Teitel J. Transmissible Agents and the Safety of Coagulation Factor Concentrates. Monograph: Facts and Figures 7 (replaces #4). Montreal; WFH 1999
-
19 Proceedings of WFH precongress symposium on Blood Component Therapy Bangkok, Thailand; October 24, 1999 Montreal; WFH
-
20 O'Mahony B. Haemophilia Societies: Challenges and Development, WFH Monograph, January 2000. Montreal; WFH 2000
-
21 Anonymous .Reaching Beyond Our Borders-A Twinning Guide for Haemophilia Organizations. Montreal; WFH 2001
-
22
Isarangkura P.
Haemophilia care in the developing world: benchmarking for excellence.
Haemophilia.
2002;
8
205-210
-
23
Evatt B L, Austin H, Leon G, Ruiz-Saez A, De Bosch N.
Haemophilia therapy: assessing the cumulative risk of HIV exposure by cryoprecipitate.
Haemophilia.
1999;
5
295-300
-
24
.
WFH/WHO recommendations, June 1997.
Haemophilia.
1998;
4(suppl 2)
64-66
-
25 Delivery of Treatment for Haemophilia. Report of a joint WHO/WFH/ISTH Meeting; February 11-13, 2002; WHO Human Genetics Programme London, United Kingdom; 2002
Brian O'Mahony Past President
WFH, Irish Haemophilia Society, Iceland House, Arran Court, Arran Quay, Dublin 7, Ireland
Email: brianihs@eircom.net
